QualityDipStocks / Health Care · Biotech
Recursion Pharmaceuticals RXRX
Outside our quality screen, so we don’t track its dips. It’s 31% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 34% from its 52-week high while revenue grew 56%
- Net cash = 23% of its market cap
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $3.88price −1%
- Off 52-wk high
- −31%
- Risk vs market
- Highbeta 2.89
4 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for RXRX: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much RXRX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 5.8× the S&P 500’s.
- Beta vs S&P 500
- 2.89
- Volatility
- 74% vs 13% SPY
- Correlation SPY
- 0.50
- Correlation QQQ
- 0.48
How it ranks
Where RXRX stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 4 measures
- Free cash flow yield−14% · free cash flow vs market capLowest 2%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+56% · vs the 12 months beforeTop 6%of 1,814
- Return on invested capital−106% · profit per dollar of capitalLowest 1%of 838
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $3.88
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
GrowthSales grew 56% to $68M over the last 12 months vs the 12 months before (SEC filings).
Balance sheetNet cash of $538M: cash and short-term investments exceed debt (Sep 30, 2026).
GrowthSales compounded 23% a year from FY2022 to FY2025.
Balance sheetDebt / equity of 0.0×, below the 0.6× median for the 126 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$312M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -541.6× over the last 12 months.
ProfitabilityLost $476M over the last 12 months (net income, SEC filings).
Cash returnsShare count up 21.5% in a year: existing holders are being diluted.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter.
All fundamentals
FCF yield -13.6% · ROE -49% · Sales +56%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −13.6%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- 33.71×
- Price / book
- 2.54×
- Market cap
- $2.3Blisted
- Enterprise value
- $1.8B
Growth
- Revenue, 12 months
- $68M
- Sales growth, 12 months
- +56.2%vs the 12 months before
- Sales growth, 3 yrs
- +23.3%/yrfrom FY2022
- Diluted EPS, 12 months
- −$0.86
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$476M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 29.2%
- Operating margin
- n/an/m
- Net margin
- n/an/m
- FCF margin
- n/an/m: revenue near zero
- Return on equity
- −49%
- Return on invested capital
- −106%
Balance sheet
- Cash & short-term inv.
- $550M
- Total debt
- $12M
- Net cash
- $538M
- Debt / equity
- 0.01×
- Interest coverage
- -541.6×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$312M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +21.5%diluted shares vs a year ago
- Stock-based comp
- $89M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Recursion Pharmaceuticals’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.3B · Sales −60%
- Free cash flow, 12 months−$0.3B
- Free-cash-flow yield-13.6%
- Gross margin0%
- Operating marginn/m
- Return on invested capital−96%
- Return on equity−57%
- Sales growth (latest quarter vs year-ago quarter)−60%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $3.83
- 52-wk lowlowest close, 1 year$2.84−25.8%
- PriceMon Nov 2 close$3.83you are here
- Market Valueavg paid since Oct 15$3.88+1.3%
- 52-wk highhighest close, 1 year$5.52+44.1%
Momentum & 52-week range
RSI 49 · 5 days +0.8%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
RXRX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Recursion Pharmaceuticals in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Biotech
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.